Update on Gene Therapy Research for Age Related Macular Degeneration.

Gyroscope Therapeutics Limited announced that the first surgeries using its proprietary OrbitTM Subretinal Delivery System (Orbit SDS) to deliver the company’s investigational gene therapy, GT005, to patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) were performed by Jeffrey Heier, M.D., at Ophthalmic Consultants of Boston. The first surgery was completed in late October for a patient enrolled in the ongoing Phase I/II FOCUS Trial and the second surgery was completed in early November for a patient enrolled in Phase II of the HORIZON Trial. Both studies are evaluating gene therapy treatment for Geographic Atrophy secondary to Age-Related Macular Degeneration.

“Dry AMD is one of the leading causes of vision loss globally and gene therapies hold tremendous promise for this disease. Delivering gene therapy directly to the site of disease through a subretinal injection is a proven approach. However, the current method requires a vitrectomy. The Orbit SDS is an innovative delivery system that could address some of the challenges surgeons and patients may experience with a vitrectomy,” said Dr. Heier, Co-President, Medical Director, Director of the Vitreoretinal Service, and Director of Retina Research at Ophthalmic Consultants of Boston

“I have been involved with the development of the Orbit SDS for several years, and I am excited to see its introduction into subretinal delivery of what we hope to be an important therapeutic intervention,” said Dr. Heier.

Learn more about these studies:

Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration

Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial

Learn more about age related macular degeneration research at OCB: